Artwork

Indhold leveret af Children's Hospital of Philadelphia. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Children's Hospital of Philadelphia eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Primary Care Perspectives: Nirsevimab (Beyfortus) - Episode 154

20:20
 
Del
 

Manage episode 377294941 series 2332133
Indhold leveret af Children's Hospital of Philadelphia. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Children's Hospital of Philadelphia eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
For the first time, a preventative medicine is available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Lori Handy, MD, MSCE, attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, details the science behind the monoclonal antibody, nirsevimab (Beyfortus) and its importance, safety and efficacy, side effects, administration and proven benefits, such as a decrease in morbidity, as shown by clinical trials; and more.
  continue reading

159 episoder

Artwork
iconDel
 
Manage episode 377294941 series 2332133
Indhold leveret af Children's Hospital of Philadelphia. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Children's Hospital of Philadelphia eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
For the first time, a preventative medicine is available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Lori Handy, MD, MSCE, attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, details the science behind the monoclonal antibody, nirsevimab (Beyfortus) and its importance, safety and efficacy, side effects, administration and proven benefits, such as a decrease in morbidity, as shown by clinical trials; and more.
  continue reading

159 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning